

Alameda Alliance for Health  
**FORMULARY UPDATE**

Effective October 31, 2013

**Alameda Alliance for Health Pharmacy & Therapeutics (P & T) Committee Decisions**

The P & T Committee reviewed the efficacy, safety, cost, and utilization profiles of the following therapeutic categories at the March 7, 2013 meeting:

- Antiemetics
- Influenza Virus Vaccines
- Antineoplastic Systemic Enzyme Inhibitors- CML
- Pancreatic Enzymes
- Upper GI
- Asthma/COPD

\*The P & T Committee approved the following modifications to the formulary for the Alliance's Medi-Cal, and Alliance Group Care programs:

Generic Name & Strength/Dosage Form	Brand Name	Committee Actions
odansetron soluble film	Zuplenz	Change to non- formulary
ranitidine capsules		Change to non- formulary
omeprazole capsules 20 mg		Change 40 mg capsule to formulary
<b>PRIOR AUTHORIZATION GUIDELINES UPDATES</b>		
Temazepam 7.5 and 22.5 mg		
Gattex (teduglutide)		
Relistor (methylnaltrexone)		
Lotronex (alosetron)		
Advair (fluticasone/salmeterol)		
Spiriva (tiotropium)		
Oral Chemotherapy Agents		
Antiemetics		
Lamisil (terbinafine)		
Singularair (montelukast)		

Generic Name & Strength/Dosage Form	Brand Name	Committee Actions
Cholinesterase Inhibitors		
Crestor (rosuvastatin)		
Humira (adalimumab)		
Hepatitis B drugs		
Cymbalta (duloxetine)		
DPP-4 Inhibitors		

\*Note: Drugs removed from the formulary will NOT be grandfathered for utilizing members unless noted otherwise under "Committee Actions."